An observational study in Infertility, Male, Azoospermia and Reproductive Disorder, sponsored by Clinique Ovo. Completed at 1 site in Canada. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-12.
Sponsored by Clinique Ovo · Observational
Normal embryonic development relies on the correct transmission of genetic information, and sperm DNA plays a crucial part in this process. Causes of poor sperm DNA integrity include unhealthy lifestyles such as smoking and exposure to gonadotoxins, as well as, obesity, varicoceles, infections, advanced paternal age and systemic disorders. An increase in DNA fragmentation in sperm has been linked to lower fertilisation rate, poorer quality embryos, lower pregnancy rate, and high miscarriages rate.
The best way for sperm selection and processing in assisted reproductive technologies (ART) should be noninvasive and cost-effective. It should also make it possible to identify high-quality spermatozoa and produce more favorable results in terms of pregnancy and live birth rates.7 Meanwhile, the microfluidic sperm separation technology is a less expensive and less invasive alternative. This method allows for the selection of motile sperm that have a normal morphology, low levels of reactive oxygen species (ROS), and low DFI
59 studies on the registry are indexed under Azoospermia; 17 are open to participants now.
This study's enrollment of 280 is above the median of 95 across 24 observational studies indexed under Azoospermia.
Browse Azoospermia studies →Clinique Ovo is the lead sponsor of 36 studies on the registry; 1 is open to participants now.
Compared within Azoospermia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infertility, Male. The counts are of registry records indexed under each term, refreshed daily. How we classify →
This retrospective study will compare and investigate ICSI outcomes in couples with high sperm DNA fragmentation using either testicular sperm (TESA) or microfluidic sperm separation device (Zymot)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Compare ICSI outcomes with high Sperm DNA fragmentation undergoing TESA (testicular sperm extraction)
Compare ICSI outcomes with high Sperm DNA fragmentation using microfluidic sperm separation device (Zymot)
Clinical Pregnancy Rate
Compare clinical pregnancy rate in couples with high Sperm DNA fragmentation
Time frame: approximately 8 weeks
Number of utilizable blastocysts obtained
Compare the number of utilizable embryos obtained in couples using TESA-ICSI vs Zymot-ICSI
Time frame: Approximately 20 days
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.